Abortion Pill Manufacturers Prepare for New Limitations One Year Post-Trump's Election
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Nov 25 2025
0mins
Should l Buy CVS?
Source: CNBC
Current Status of Mifepristone: The abortion pill mifepristone remains available under existing federal rules, with the FDA allowing telehealth prescriptions and mail delivery, despite potential threats from a safety review and legal challenges.
Impact of Political Changes: The Trump administration's influence on the FDA and potential reinterpretation of laws like the Comstock Act could significantly restrict access to mifepristone, despite its long-standing safety record and recent approval of a generic version.
Market and Legal Landscape: Drug manufacturers are preparing for possible regulatory changes that could affect the supply chain and access to mifepristone, while ongoing litigation and state-level restrictions create a complex environment for abortion providers.
Challenges for Abortion Providers: Despite some states strengthening protections for providers, many clinics face operational challenges due to funding cuts, staff shortages, and legal risks, leading to a chilling effect on prescribing mifepristone across state lines.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy CVS?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on CVS
Wall Street analysts forecast CVS stock price to rise
17 Analyst Rating
16 Buy
1 Hold
0 Sell
Strong Buy
Current: 77.300
Low
91.00
Averages
96.71
High
105.00
Current: 77.300
Low
91.00
Averages
96.71
High
105.00
About CVS
CVS Health Corporation is a health solutions company. The Company's segments include Health Care Benefits, Health Services, Pharmacy & Consumer Wellness and Corporate/Other. The Health Care Benefits segment offers a broad range of traditional, voluntary and consumer-directed health insurance products and related services, including medical, pharmacy, dental and behavioral health plans, PDPs and Medicaid health care management services. The Health Services segment provides a full range of pharmacy benefit management (PBM) solutions through its CVS Caremark operations and delivers health care services in its medical clinics, virtually, and in the home. The Pharmacy & Consumer Wellness segment dispenses prescriptions in its CVS Pharmacy retail locations and, through its infusion operations, provides ancillary pharmacy services including pharmacy patient care programs, and vaccination administration, and sells a wide assortment of health and wellness products and general merchandise.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
CVS Health Rises 3.3%, Elevance Increases 3.2%, Cigna Gains 1.3%, Humana Climbs 2.9%, Molina Healthcare Up 3% in Premarket Trading
CVS Health Growth: CVS Health reported a growth of 3.3% in its recent performance metrics.
Elevance Health Performance: Elevance Health experienced a 3.2% increase in its financial results.
Cigna's Increase: Cigna saw a 1.3% rise in its performance indicators.
Humana and Molina Health Care: Humana's growth was recorded at 2.9%, while Molina Health Care reported a 3% increase.
See More
U.S. Health Insurer Stocks Climb in Premarket Trading Following UnitedHealth's Q1 Profit Beat
Health Insurers' Stock Performance: U.S. health insurers' shares have seen a rise in the premarket following reports from UnitedHealth indicating a profit in Q1 that exceeds estimates.
Market Reaction: The positive earnings report from UnitedHealth has contributed to an overall increase in investor confidence in the health insurance sector.
See More
Investment Comparison: CVS Health vs. Novo Nordisk
- Diversification Advantage: CVS Health, through its Aetna subsidiary, is one of the largest health insurers in the U.S., and while diversification may spread resources thin, it is expected to benefit in the long run as demand for medical products and services increases.
- Market Leadership: CVS Health's leadership in various healthcare niches, supported by strong relationships with patients, doctors, and payers, positions it well to navigate regulatory barriers and market challenges effectively.
- Concentration Risks for Novo Nordisk: Novo Nordisk's focus on metabolic diseases has made it a leader in the diabetes drug market, but its declining competitiveness in the weight loss market and recent clinical setbacks could significantly worsen its financial results.
- Investment Outlook Comparison: Although Novo Nordisk's stock has declined significantly over the past two years, its deep pipeline in weight loss could lead to recovery in the coming years, making both companies attractive options for long-term investors.
See More
Market Dynamics and Company Earnings Analysis
- ASML Surpasses Expectations: ASML's first-quarter results significantly exceeded expectations, and the company raised its 2026 guidance, indicating strong demand for semiconductor manufacturing equipment, which could further boost the stock prices of related companies.
- Morgan Stanley's Strong Quarter: Morgan Stanley reported substantial beats in equities and fixed-income trading, leading to a more than 2% increase in its stock price, showcasing its competitive edge in investment banking, with CEO Ted Pick's leadership gaining market recognition.
- Wells Fargo's Underwhelming Performance: Although Wells Fargo reported decent quarterly results, concerns over its private credit portfolio led analysts to lower its price target and remove it from their best ideas list, resulting in the stock stabilizing after a 5.7% decline.
- Johnson & Johnson Price Target Hikes: Following its earnings report, Barclays and Stifel raised Johnson & Johnson's price targets to $255 and $250 respectively, reflecting market optimism about its strong pharmaceutical portfolio, particularly driven by cancer treatments and Tremfya.
See More
Medicare Payment Increase Boosts CVS Stock Recovery
- Impact of Medicare Policy: The CMS's finalized Medicare payment increase of nearly 2.5% significantly improves the profitability outlook for CVS and other healthcare stocks, leading to a stock price rebound compared to the previously proposed 0.09% increase.
- Upgraded Earnings Expectations: Analysts project CVS's earnings per share to reach between $7 and $7.20 in 2026, with the increase in Medicare payments likely enhancing CVS's profitability and boosting market confidence.
- Stock Valuation Potential: Currently trading at around 11 times forward earnings, CVS could see its stock price rise to $90 or $100 if it narrows the valuation gap with competitors like UnitedHealth Group, offering substantial investment returns.
- Stable Dividend Yield: With a forward dividend yield of 3.4%, CVS not only provides steady income but also attracts long-term investors, further supporting the upward momentum of its stock price.
See More
CVS Health Stock Rebounds on Improved Medicare Payment Rates
- Medicare Rate Increase: The Centers for Medicare & Medicaid Services (CMS) finalized a 2.5% increase in Medicare payment rates, significantly better than the previously proposed 0.09%, which is expected to enhance CVS Health's profitability outlook and boost investor confidence.
- Earnings Forecast Adjustment: Analysts project CVS Health's earnings per share (EPS) to reach between $7 and $7.20 in 2026, with the increased Medicare payments potentially driving double-digit earnings growth in 2027, further propelling the stock price upward.
- Valuation Gap: CVS Health's current stock price trades at about 11 times forward earnings, while peers like UnitedHealth Group trade at 15 to 20 times; if CVS can partially close this valuation gap, its stock price could reasonably rise to $90 or $100, offering substantial investment returns.
- Stable Dividend Yield: With a forward dividend yield of 3.4%, CVS Health not only provides steady returns but, combined with the positive changes in Medicare policy, presents an attractive investment opportunity.
See More
CVS Health Rises 3.3%, Elevance Increases 3.2%, Cigna Gains 1.3%, Humana Climbs 2.9%, Molina Healthcare Up 3% in Premarket Trading
CVS Health Growth: CVS Health reported a growth of 3.3% in its recent performance metrics.
Elevance Health Performance: Elevance Health experienced a 3.2% increase in its financial results.
Cigna's Increase: Cigna saw a 1.3% rise in its performance indicators.
Humana and Molina Health Care: Humana's growth was recorded at 2.9%, while Molina Health Care reported a 3% increase.
See More
U.S. Health Insurer Stocks Climb in Premarket Trading Following UnitedHealth's Q1 Profit Beat
Health Insurers' Stock Performance: U.S. health insurers' shares have seen a rise in the premarket following reports from UnitedHealth indicating a profit in Q1 that exceeds estimates.
Market Reaction: The positive earnings report from UnitedHealth has contributed to an overall increase in investor confidence in the health insurance sector.
See More
Investment Comparison: CVS Health vs. Novo Nordisk
- Diversification Advantage: CVS Health, through its Aetna subsidiary, is one of the largest health insurers in the U.S., and while diversification may spread resources thin, it is expected to benefit in the long run as demand for medical products and services increases.
- Market Leadership: CVS Health's leadership in various healthcare niches, supported by strong relationships with patients, doctors, and payers, positions it well to navigate regulatory barriers and market challenges effectively.
- Concentration Risks for Novo Nordisk: Novo Nordisk's focus on metabolic diseases has made it a leader in the diabetes drug market, but its declining competitiveness in the weight loss market and recent clinical setbacks could significantly worsen its financial results.
- Investment Outlook Comparison: Although Novo Nordisk's stock has declined significantly over the past two years, its deep pipeline in weight loss could lead to recovery in the coming years, making both companies attractive options for long-term investors.
See More
Market Dynamics and Company Earnings Analysis
- ASML Surpasses Expectations: ASML's first-quarter results significantly exceeded expectations, and the company raised its 2026 guidance, indicating strong demand for semiconductor manufacturing equipment, which could further boost the stock prices of related companies.
- Morgan Stanley's Strong Quarter: Morgan Stanley reported substantial beats in equities and fixed-income trading, leading to a more than 2% increase in its stock price, showcasing its competitive edge in investment banking, with CEO Ted Pick's leadership gaining market recognition.
- Wells Fargo's Underwhelming Performance: Although Wells Fargo reported decent quarterly results, concerns over its private credit portfolio led analysts to lower its price target and remove it from their best ideas list, resulting in the stock stabilizing after a 5.7% decline.
- Johnson & Johnson Price Target Hikes: Following its earnings report, Barclays and Stifel raised Johnson & Johnson's price targets to $255 and $250 respectively, reflecting market optimism about its strong pharmaceutical portfolio, particularly driven by cancer treatments and Tremfya.
See More
Medicare Payment Increase Boosts CVS Stock Recovery
- Impact of Medicare Policy: The CMS's finalized Medicare payment increase of nearly 2.5% significantly improves the profitability outlook for CVS and other healthcare stocks, leading to a stock price rebound compared to the previously proposed 0.09% increase.
- Upgraded Earnings Expectations: Analysts project CVS's earnings per share to reach between $7 and $7.20 in 2026, with the increase in Medicare payments likely enhancing CVS's profitability and boosting market confidence.
- Stock Valuation Potential: Currently trading at around 11 times forward earnings, CVS could see its stock price rise to $90 or $100 if it narrows the valuation gap with competitors like UnitedHealth Group, offering substantial investment returns.
- Stable Dividend Yield: With a forward dividend yield of 3.4%, CVS not only provides steady income but also attracts long-term investors, further supporting the upward momentum of its stock price.
See More
CVS Health Stock Rebounds on Improved Medicare Payment Rates
- Medicare Rate Increase: The Centers for Medicare & Medicaid Services (CMS) finalized a 2.5% increase in Medicare payment rates, significantly better than the previously proposed 0.09%, which is expected to enhance CVS Health's profitability outlook and boost investor confidence.
- Earnings Forecast Adjustment: Analysts project CVS Health's earnings per share (EPS) to reach between $7 and $7.20 in 2026, with the increased Medicare payments potentially driving double-digit earnings growth in 2027, further propelling the stock price upward.
- Valuation Gap: CVS Health's current stock price trades at about 11 times forward earnings, while peers like UnitedHealth Group trade at 15 to 20 times; if CVS can partially close this valuation gap, its stock price could reasonably rise to $90 or $100, offering substantial investment returns.
- Stable Dividend Yield: With a forward dividend yield of 3.4%, CVS Health not only provides steady returns but, combined with the positive changes in Medicare policy, presents an attractive investment opportunity.
See More
